Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

被引:20
作者
Caslake, Muriel J. [1 ]
Packard, Chris J.
Robertson, Michele [2 ]
Cooney, Josephine
Nelson, Jeanenne J. [3 ]
Ford, Ian [2 ]
Gaw, Allan [4 ]
Jukema, J. Wouter [5 ]
Macfarlane, Peter W.
Stott, David J.
Shepherd, James
机构
[1] Univ Glasgow, Western Infirm Glasgow, Vasc Biochem Grp, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland
[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow G11 6NT, Lanark, Scotland
[3] GlaxoSmithKline, Worldwide Epidemiol, Res Triangle Pk, NC USA
[4] NHS Greater Glasgow & Clyde, Glasgow Clin Res Facil, Glasgow, Lanark, Scotland
[5] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
关键词
Lipoprotein-associated phospholipids A(2); Elderly; Prosper; Inflammatory markers; Coronary heart disease risk; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; ATHEROSCLEROSIS RISK; ISCHEMIC-STROKE; PREDICTION; EVENTS; MARKERS; WOMEN;
D O I
10.1016/j.atherosclerosis.2009.10.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an inflammatory biomarker that circulates mainly bound to LDL. We evaluated the association of Lp-PLA(2) with vascular events in the elderly where the importance of LDL is diminished as a risk factor for coronary disease. Methods: Mass and activity of Lp-PLA(2) were related to risk over 3.2 years for vascular events (definite or suspected death from CHD, non-fatal MI, fatal or non-fatal stroke) in the 2804 men and 3000 women age 70-82 years in the Prospective Study of Pravastatin in the Elderly (PROSPER). Results: Lp-PLA(2) showed a moderate, positive association with risk of a vascular event with hazard ratios of 1.25 (confidence interval (CI) 1.02-1.54) for mass and 1.39 (CI 1.14-1.70) for activity for top versus bottom quartile. Risk associations were attenuated when classical risk factors, lipids and in. ammatory markers - C-reactive protein and white cell count - were included in the models. Lp-PLA(2) was unrelated to stroke risk. Inclusion of all three in. ammatory markers in multivariate models negated the association of HDL cholesterol with risk (hazard ratio 0.98; CI 0.88-1.10) and increased prediction of coronary events; the C statistic rose from 63.2% to 64.4% (P < 0.001). Conclusion: In elderly people Lp-PLA(2), alongside other inflammatory indices, is a potential biomarker for vascular events, particularly CHD. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:28 / 34
页数:7
相关论文
共 30 条
[1]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, P ;
Folsom, AR ;
Chambless, LE ;
Myerson, M ;
Wu, KK ;
Sharrett, AR ;
Boerwinkle, E .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (21) :2479-2484
[2]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[3]   C-reactive protein and other inflammatory risk markers in acute coronary syndromes [J].
Blake, GJ ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :37S-42S
[4]   Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144
[5]   Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke [J].
Caslake, MJ ;
Packard, CJ .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (10) :529-535
[6]   Platelet-activating factor acetylhydrolase: is it good or bad for you? [J].
Chen, CH .
CURRENT OPINION IN LIPIDOLOGY, 2004, 15 (03) :337-341
[7]   C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J].
Danesh, J ;
Wheeler, JG ;
Hirschfield, GM ;
Eda, S ;
Eiriksdottir, G ;
Rumley, A ;
Lowe, GDO ;
Pepys, MB ;
Gudnason, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) :1387-1397
[8]   High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke [J].
Elkind, Mitchell S. V. ;
Tai, Wanling ;
Coates, Kristen ;
Paik, Myunghee C. ;
Sacco, Ralph L. .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) :2073-2080
[9]   An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers - The atherosclerosis risk in communities study [J].
Folsom, Aaron R. ;
Chambless, Lloyd E. ;
Ballantyne, Christie M. ;
Coresh, Josef ;
Heiss, Gerardo ;
Wu, Kenneth K. ;
Boerwinkle, Eric ;
Mosley, Thomas H., Jr. ;
Sorlie, Paul ;
Diao, Guoqing ;
Sharrett, A. Richey .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (13) :1368-1373
[10]   A prospective study of pravastatin in the elderly at risk (PROSPER): Screening experience and baseline characteristics [J].
Ford, I ;
Blauw, GJ ;
Murphy, MB ;
Shepherd, J ;
Cobbe, SM ;
Bollen, ELEM ;
Buckley, BM ;
Jukema, JW ;
Hyland, M ;
Gaw, A ;
Lagaay, AM ;
Perry, IJ ;
Macfarlane, PW ;
Norrie, J ;
Meinders, AE ;
Sweeney, BJ ;
Packard, CJ ;
Westendorp, RGJ ;
Twomey, C ;
Stott, DJ .
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2002, 3 (1)